Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Goodman

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Medical Care Research and Review : MCRR|September 18, 2004
Opportunities and challenges for measuring cost, quality, and clinical effectiveness in health carePaul A Fishman, Mark C Hornbrook, Richard T Meenan, et al.
Pediatrics|May 3, 2006
The safety of trivalent influenza vaccine among healthy children 6 to 24 months of ageMichael J Goodman, James D Nordin, Peter Harper, et al.
Drug Design, Development and Therapy|July 3, 2020
Are Laboratory Parameter (Biomarker) Values Similar to the Healthy Volunteer Reference Range in Individuals with DiabetesDavid A Brott, Michael J Goodman, Richard P Hermann, et al.
Pediatrics|July 14, 2010
Henoch-Schölein purpura and polysaccharide meningococcal vaccineMichael J Goodman, James D Nordin, Edward A Belongia, et al.
American Journal of Preventive Medicine|June 17, 2006
Colorectal cancer screening: health impact and cost effectivenessMichael V Maciosek, Leif I Solberg, Ashley B Coffield, et al.
American Journal of Preventive Medicine|June 17, 2006
Repeated tobacco-use screening and intervention in clinical practice: health impact and cost effectivenessLeif I Solberg, Michael V Maciosek, Nichol M Edwards, et al.
American Journal of Preventive Medicine|June 17, 2006
Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and olderMichael V Maciosek, Leif I Solberg, Ashley B Coffield, et al.
Drug Design, Development and Therapy|September 21, 2018
Are laboratory parameter (biomarker) values similar to the healthy volunteer reference range in all patient populations?David A Brott, Michael J Goodman, Richard P Hermann, et al.
Journal of Cachexia, Sarcopenia and Muscle|May 16, 2013
Development of a practical screening tool to predict low muscle mass using NHANES 1999-2004Michael J Goodman, Sameer R Ghate, Panagiotis Mavros, et al.
American Journal of Preventive Medicine|June 17, 2006
Priorities among effective clinical preventive services: results of a systematic review and analysisMichael V Maciosek, Ashley B Coffield, Nichol M Edwards, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Medical Care Research and Review : MCRR|September 18, 2004
Opportunities and challenges for measuring cost, quality, and clinical effectiveness in health carePaul A Fishman, Mark C Hornbrook, Richard T Meenan, et al.
Pediatrics|May 3, 2006
The safety of trivalent influenza vaccine among healthy children 6 to 24 months of ageMichael J Goodman, James D Nordin, Peter Harper, et al.
Drug Design, Development and Therapy|July 3, 2020
Are Laboratory Parameter (Biomarker) Values Similar to the Healthy Volunteer Reference Range in Individuals with DiabetesDavid A Brott, Michael J Goodman, Richard P Hermann, et al.
Pediatrics|July 14, 2010
Henoch-Schölein purpura and polysaccharide meningococcal vaccineMichael J Goodman, James D Nordin, Edward A Belongia, et al.
American Journal of Preventive Medicine|June 17, 2006
Colorectal cancer screening: health impact and cost effectivenessMichael V Maciosek, Leif I Solberg, Ashley B Coffield, et al.
American Journal of Preventive Medicine|June 17, 2006
Repeated tobacco-use screening and intervention in clinical practice: health impact and cost effectivenessLeif I Solberg, Michael V Maciosek, Nichol M Edwards, et al.
American Journal of Preventive Medicine|June 17, 2006
Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and olderMichael V Maciosek, Leif I Solberg, Ashley B Coffield, et al.
Drug Design, Development and Therapy|September 21, 2018
Are laboratory parameter (biomarker) values similar to the healthy volunteer reference range in all patient populations?David A Brott, Michael J Goodman, Richard P Hermann, et al.
Journal of Cachexia, Sarcopenia and Muscle|May 16, 2013
Development of a practical screening tool to predict low muscle mass using NHANES 1999-2004Michael J Goodman, Sameer R Ghate, Panagiotis Mavros, et al.
American Journal of Preventive Medicine|June 17, 2006
Priorities among effective clinical preventive services: results of a systematic review and analysisMichael V Maciosek, Ashley B Coffield, Nichol M Edwards, et al.
Pageof 4